Categorynews

BioTime Announces Appointment of General Counsel

May 22, 2019 Off By BusinessWire

ALAMEDA, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24BTX&src=ctag" target="_blank"gt;$BTXlt;/agt; lt;a href="https://twitter.com/hashtag/AMD?src=hash" target="_blank"gt;#AMDlt;/agt;–BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company developing cellular therapies for unmet medical
needs, today announced that it has appointed Chase C. Leavitt as
BioTime’s General Counsel and Corporate Secretary.

“We’re extremely fortunate to have Chase join us and bring his extensive
public company experience as well as a strong track record to the role
of general counsel,” stated Brian M. Culley, Chief Executive Officer of
BioTime. “Chase’s diverse industry experience including SEC compliance,
corporate governance, strategic transactions and mergers and
acquisitions will be instrumental as BioTime continues to execute on its
clinical and operational plans.”

Prior to joining BioTime, Mr. Leavitt served as Vice President of Legal
Affairs of Tang Capital Management, LLC, a life sciences-focused
investment company, and its affiliate Odonate Therapeutics, Inc., a
publicly traded pharmaceutical company, from June 2018 to May 2019. From
May 2017 to May 2018, Mr. Leavitt served as the Deputy General Counsel
of Switch, Inc., a publicly traded technology company, and previously
served as its Associate General Counsel from July 2014 to May 2017. From
2007 to 2014, Mr. Leavitt was a corporate attorney at Latham & Watkins
LLP, where his practice focused on public company representation,
mergers and acquisitions and capital markets, serving life sciences and
technology companies. Mr. Leavitt received a B.S. in Business
Administration and a J.D. from the University of Southern California and
is admitted to practice law by the State Bar of California.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company developing new
cellular therapies for unmet medical needs. BioTime’s programs are based
on its proprietary cell-based therapy platform and associated
development and manufacturing capabilities. With this platform BioTime
develops and manufactures specialized, terminally-differentiated human
cells from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed either to replace or support cells
that are dysfunctional or absent due to degenerative disease or
traumatic injury, or administered as a means of helping the body mount
an effective immune response to cancer. BioTime’s clinical assets
include (i) OpRegen^®, a retinal pigment epithelium transplant
therapy in Phase I/IIa development for the treatment of dry age-related
macular degeneration, the leading cause of blindness in the developed
world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase
I/IIa development for the treatment of acute spinal cord injuries; and
(iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting
dendritic cells currently in Phase I development for the treatment of
non-small cell lung cancer. For more information, please visit www.biotimeinc.com
or follow the Company on Twitter @BioTimeBTX.